Description
Description
SPECIFICATION
5ML
GENERIC
Moxifloxacin , Dexamethasone Sodium Phosphate
About
Moxifloxacin is a synthetic fluoroquinolone antibacterial agent active in vitro against a broad spectrum of Gram-positive and Gram-negative ocular pathogens, atypical microorganisms and anaerobes. The antibacterial action of Moxifloxacin results from inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. Dexamethasone is a highly potent and long-acting glucocorticoid. The actions of corticosteroids are mediated by the binding of the corticosteroid molecules to receptor molecules located within sensitive cells. Corticosteroids will inhibit phospholipase A2 thereby preventing the generation of substances which mediate inflammation, for example, prostaglandins. Corticosteroids also produce a marked, though transient, lymphocytopaenia. This depletion is due to redistribution of the cells, the T lymphocytes being affected to a greater degree than the B lymphocytes. Lymphokine production is reduced, as is the sensitivity of macrophages to activation by lymphokines. Corticosteroids also retard epithelial regeneration, diminish post-inflammatory neo- vascularisation and reduce towards normal levels the excessive permeability of inflamed capillaries. The actions of corticosteroids described above are exhibited by dexamethasone and they all contribute to its anti-inflammatory effect.
Indication
Steroid-responsive inflammatory ocular condition for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Post-operative inflammation and any other ocular inflammation associated with infection.
Side Effects
Conjunctival irritation , increased lacrimation , keratitis and papillary conjunctivitis, Secondary infection.
Drug Interactions
Atropine and related compounds, phenytoin, phenobarbitone, ephedrine and rifampicin.
When not to Use
It is contraindicated in patients with a history of hypersensitivity to Moxifloxacin, to other quinolones, or to any of the components in this medication.
Precaution
In patients receiving systemically administered quinolones, including Moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose.